ERBB2 and gastric cancer: Patients with metastatic HER2-overexpressing GC and GEJ cancer that has progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy and are suitable for chemotherapy (2nd-line or 3rd-line)